Please assess the completion status of the following clinical trial:

Trial Title: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female infants born at \>36 weeks of gestation and 2 months of age at the time of consent.~* Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.~Exclusion Criteria:~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)~* Major known congenital malformation or serious chronic disorder~* Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results~* Previous receipt of \>1 dose of hepatitis B vaccine; or receipt of a single hepatitis B vaccine dose administered at \>30 days old, or previous receipt of any licensed or investigational pneumococcal vaccine, or planned receipt through study participation

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- 20-valent pneumococcal conjugate vaccine (Type: EXPERIMENTAL): Pneumococcal conjugate vaccine
- 13-valent pneumococcal conjugate vaccine (Type: ACTIVE_COMPARATOR): Pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).